Financial Data and Key Metrics Changes - The company reported record revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in the same period last year [7][26] - Gross profit for Q4 2025 increased to $12 million, with a gross profit margin of 62.6%, slightly down from 63% in the prior year [30] - Net loss attributable to stockholders was $1.3 million or $0.03 per share for Q4 2025, compared to a net loss of $4.6 million or $0.12 per share in the prior year [32] Business Line Data and Key Metrics Changes - Revenue from the surgical aesthetics segment increased 38% to $16.7 million in Q4 2025, driven by sales of the AYON body contouring system [27][28] - OEM segment sales increased 16% to $2.5 million in Q4 2025, attributed to increased sales volume to existing customers [29] Market Data and Key Metrics Changes - Domestic revenue increased 42% year-over-year to $15 million, while international revenue increased 15% year-over-year to $4.2 million [29] - The company noted a significant shift in the market driven by the adoption of GLP-1 drugs for weight loss, leading to increased demand for aesthetic treatments [17][19] Company Strategy and Development Direction - The company is focused on expanding the AYON platform and enhancing its market position by submitting a follow-up application for power liposuction, expected to receive clearance in mid-2026 [14][15] - Apyx Medical is strengthening its commercial organization by acquiring high-caliber sales talent to support growth and market share [21][68] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market's reaction to AYON, indicating that the adoption curve is still in the early stages and that the company is well-positioned to capitalize on market shifts [11][20] - The company anticipates total revenue for 2026 to be in the range of $57.5 million to $58.5 million, reflecting a 9%-11% increase compared to 2025 [36] Other Important Information - Cash used in operating activities decreased to $2.5 million in Q4 2025 from $2.9 million in the prior year, with total cash burn for the year decreasing to $8 million from $18.7 million [33][34] - The company had cash and cash equivalents of $31.7 million as of December 31, 2025, and expects to maintain cash flow through 2027 [35] Q&A Session Summary Question: Can you provide more details on handpiece and capital equipment sales? - Management indicated that growth in Q4 was driven by AYON, with domestic sales growing almost 50% [50] Question: What is the pricing strategy for AYON? - The list price of AYON is approximately $360,000, which includes the Apyx One generator and complementary components [53] Question: What feedback have you received from customers regarding AYON? - Customers have expressed strong satisfaction with AYON, with requests for the power-assisted handpiece expected in the first half of the year [58] Question: What are the plans for AYON's international expansion? - Currently, AYON is approved only in the U.S., with plans to register in key countries like Europe and Brazil [74] Question: What is the expected cash flow situation moving forward? - The company plans to be cash flow positive no later than Q4 2026 [83]

Core Insights - Eli Lilly reported Q4 earnings that exceeded analyst expectations, with a profit of $7.54 per share on sales of $19.3 billion, compared to forecasts of $6.93 per share on $17.9 billion in sales [1] - Despite strong earnings, Eli Lilly's stock fell 6% due to competitive pressures from Hims & Hers Health, which announced a new "needle-free" GLP-1 weight loss pill [1][3] Group 1: Eli Lilly's Performance - Eli Lilly's Q4 earnings beat expectations, forecasting full-year 2026 earnings between $33.50 and $35 per share [1] - The company achieved significant sales driven by injectable GLP-1 weight loss drugs Mounjaro and Zepbound in 2025 [2] Group 2: Competitive Landscape - Hims & Hers Health introduced a compounded semaglutide pill priced at $49 for the first month, which is significantly lower than Eli Lilly's Zepbound price of $299 for the lowest-dose formulation [3][4] - Hims & Hers plans to increase the price of its GLP-1 pill to $99 per month after the introductory period, but it remains competitive compared to Novo Nordisk's pricing [4][5] - Novo Nordisk offers its injectable Wegovy at $199 and its pill form at $149, indicating a competitive pricing environment for GLP-1 drugs [4]

Group 1 - Apyx Medical is positioning itself as a leader in the surgical aesthetics market, emphasizing that surgical aesthetics provide durable and transformational results for patients [4] - The company is launching a new product, AYON, which will be a focal point of the event [3] - The market dynamics have been notably influenced by the introduction of GLP-1 drugs for weight loss, which has changed the landscape of surgical aesthetics [4] Group 2 - The event features Dr. Vanek as a key opinion leader (KOL), who will share his experiences with the AYON product [2][3] - The agenda includes an introduction by the CEO, a discussion on the commercial launch of AYON, and a Q&A session at the end [3]